FDA Approves Mavyret for Hepatitis C
Combo drug is first approved therapy for hepatitis C to require as few as eight weeks of treatment
Stopping Statins After Initial Stroke Raises Risk of Recurrence
Findings based on patients discontinuing therapy three to six months after stroke
Genetic Variation Impacts Pharmacokinetics of Exemestane
Significant differences in plasma exemestane area under the curve for OATP1B1 genotype groups
In Utero Psychotropics + Opioids Up Neonatal Drug Withdrawal
Risk of withdrawal increased two-fold with in utero exposure to two or more psychotropics plus opioids
APA: Reasons for Underuse of Buprenorphine by PCPs ID’d
Doctors not willing to increase prescribing due to lack of belief in agonist tx, lack of time for more patients
FDA Approves New Treatment for Acute Myeloid Leukemia
Vyxeos combines two previously approved drugs -- daunorubicin and cytarabine
Ipragliflozin Beneficial in T2DM Complicated by Liver Disease
Effect similar to pioglitazone, with reduction in body weight, abdominal fat only for ipragliflozin
Canagliflozin Delays Increase in Certain CV Biomarkers in T2DM
Canagliflozin may reduce CV, heart failure risk over two years versus placebo in older patients with T2DM
ABP 501, Adalimumab Biosimilar, Safe and Effective, for Psoriasis
Findings based on comparison over 52 weeks, including single transition
Inappropriate Med Use High in Cognitively Impaired Seniors
Prevalence of potentially inappropriate medication use higher for frail seniors with cognitive impairment
